MedTrace Logo

Safety of Autologous Cord Blood Cells for Preterm Infants.

NCT03760900 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2020-06-02

No results posted yet for this study

Summary

To assess the safety of autologous volume- and red blood cell (RBC)-reduced non-cryopreserved umbilical cord blood (UCB) cell infusion to preterm infants.

Conditions

  • Safety Issues
  • Effect of Drugs
  • Neonatal Death

Interventions

COMBINATION_PRODUCT

Autologous Umbilical Cord Blood Stem Cells Therapy

Autologous Umbilical Cord Blood Stem Cells Therapy,the dose is 5×107cells/kg, within 24 hours after birth

Sponsors & Collaborators

  • Guangdong Women and Children Hospital

    lead OTHER

Principal Investigators

  • jie Yang, PHD · Guangdong Women and Children Hospital and Healthy Institutes

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
37 Weeks
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-01
Primary Completion
2010-01-01
Completion
2016-06-05

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03760900 on ClinicalTrials.gov